Study design

prospective, single-arm, IDEAL stage 2b study

Study time

2016.12-2017.7

Country

United States

Object

Men who met the criteria: (I) PSA ≤15 ng/mL, (II) stage ≤cT2, (III) domint unilateral lesion with Gleason ≤4+3 with any number or percentage (%) of cores involved ipsilaterally on biopsy, (IV) no primary Gleason ≥4 contralaterally, and (V) preoperative erectile function score (IIEF-5/SHIM) of ≥17 with/without PDE-5i were included in this prospective, single-arm, IDEAL stage 2b study

Robots remarks

 patients undergoing robotic precision prostatectomy 

Sample size

25

Topic classification

Other treatments

Keypoint

Precision prostatectomy is feasible, technically safe, and offers excellent postoperative functiol results. At 36 months of follow-up, the oncological outcomes and secondary procedure rates appear to be at-par with the ablative forms of focal therapy.

Year